OPALINSKI Isabelle

Thèmes de recherche :

Renoux B., Raes F., Legigan T., Péraudeau E., Eddhif B., Poinot P., Tranoy-Opalinski I., Alsarraf J., Koniev O., Kolodych S., Lerondel S., Le Pape A., Clarhaut J., Papot S., Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers, Chem. Sci. (2017) 8, 3427-3433. DOI: 10.1039/c7sc00472a.
Barat R., Legigan T., Tranoy-Opalinski I., Renoux B., Peraudeau E., Clarhaut J., Poinot P., Fernandes A. E., Aucagne V., Leigh D. A. and Papot S., A mechanically interlocked molecular system programmed for the delivery of an anticancer drug, Chem Sci. (2015) 6, 2608-2613. DOI: 10.1039/c5sc00648a.

Legigan T., Clarhaut J., Tranoy-Opalinski I., Monvoisin A., Renoux B., Thomas M., Lepape A., Lerondel S., Papot S. The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumours in Prodrug Monotherapy, Angew. Chem. Int. Ed. (2012) 51, 11606-11610 (Inside cover) DOI: 10.1002/anie.201204935.

Thomas M., Clarhaut J., Strale P.-O., Tranoy-Opalinski I., Roche J., Papot S. A Galactosidase-Responsive “Trojan Horse” for the Selective Targeting of Folate Receptor-Positive Tumor Cells, ChemMedChem (2011) 6, 1006-1010. DOI: 10.1002/cmdc.201100114.

Grinda M., Clarhaut J., Tranoy-Opalinski I., Renoux B., Monvoisin A., Cronier L., Papot S. A Heterodimeric Glucuronide Prodrug for Cancer Tritherapy: the Double Role of the Chemical Amplifier, ChemMedChem (2011) 6, 2137-2141. DOI: 10.1002/cmdc.201100355.